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ABSTRACT
Early detection of gastric cancers saves lives, but remains a diagnostic challenge. 
In this study, we aimed to identify cell-surface biomarkers of early gastric cancer. We 
hypothesized that a subset of plasma membrane proteins induced by the Helicobacter 
pylori oncoprotein CagA will be retained in early gastric cancers through non-oncogene 
addiction. An inducible system for expression of CagA was used to identify differentially 
upregulated membrane protein transcripts in vitro. The top hits were then analyzed in 
gene expression datasets comparing transcriptome of gastric cancer with normal tissue, to 
focus on markers retained in cancer. Among the transcripts enriched upon CagA induction 
in vitro, a significant elevation of CEACAM6 was noted in gene expression datasets of 
gastric cancer. We used quantitative digital immunohistochemistry to measure CEACAM6 
protein levels in tissue microarrays of gastric cancer. We demonstrate an increase in 
CEACAM6 in early gastric cancers, when compared to matched normal tissue, with an 
AUC of 0.83 for diagnostic validity. Finally, we show that a fluorescently conjugated 
CEACAM6 antibody binds avidly to freshly resected gastric cancer xenograft samples and 
can be detected by endoscopy in real time. Together, these results suggest that CEACAM6 
upregulation is a cell surface response to H. pylori CagA, and is retained in early gastric 
cancers. They highlight a novel link between CEACAM6 expression and CagA in gastric 
cancer, and suggest CEACAM6 to be a promising biomarker to aid with the fluorescent 
endoscopic diagnosis of early neoplastic lesions in the stomach.
INTRODUCTION
The clinical need for an endoscopic marker of 
early gastric cancer
Gastric cancer is a leading cause of mortality from 
neoplastic disease, and is particularly prevalent in Asian 
populations [1]. Symptomatology is rare and non-specific 
in the early stages of the disease [2] necessitating screening 
by endoscopy to differentiate benign gastric conditions 
from cancer. Early diagnosis of gastric cancer through 
endoscopic methods, and its treatment by submucosal 
resection has enabled 5-year survival rates of up to 95% in 
cohort studies [3, 4]. In contrast, the overall 5-year survival 
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of all patients with gastric cancer, as determined from the 
NCI Surveillance Epidemiology and End Results database 
(http://seer.cancer.gov) is only 26%, as many of the patients 
have regional or distant spread at the time of diagnosis. This 
has resulted in the categorization of ‘Early Gastric Cancer’ 
(EGC) as a unique entity, defined by T1 disease, and good 
clinical outcomes. However, early diagnosis of EGC and the 
premalignant stage, gastric intestinal metaplasia (GIM), is 
not trivial using conventional endoscopic techniques. There 
is therefore an urgent need for improved methods to facilitate 
early diagnosis of cancer and pre-malignant lesions of the 
stomach, and thereby ensure early and effective treatment.
The primary method of diagnosis of gastric cancer 
and pre-malignant conditions relies on accurate endoscopic 
visualization and tissue sampling through biopsies. The 
current gold standard is white light endoscopy, however this 
is fraught with limitations, primarily due to reliance on the 
skill of the operator in terms of adequate visualization and 
tissue sampling. Early cancers and dysplastic lesions are 
often not obvious to visual inspection, and require years of 
experience to identify [5]. Furthermore, variation in disease 
prevalence has led to variations in endoscopic skill levels 
in different parts of the world, with missed diagnosis rates 
of 8-35% [6, 7]. The development of methods to improve 
the contrast between normal and early cancerous tissue is 
likely to have a significant benefit in the global management 
of this disease. Several image-enhanced tools currently aid 
in making the diagnosis of gastric cancer [8, 9], including 
narrow band imaging and auto fluorescence imaging, which 
rely on the inherent fluorescent properties of cancer tissue. 
However, these techniques are not adequately sensitive and 
specific for the routine diagnosis of early gastric cancers. 
Methods that rely on or exploit the molecular differences 
in normal and abnormal tissue are not widely studied in 
the diagnosis of early gastric cancer [10]. By utilizing cell 
surface markers combined with a fluorescent probe, we 
hypothesize greater image capturing capabilities for the real-
time diagnosis of early gastric cancer and ultimately real-
time treatment. This is particularly attractive in view of the 
move towards screening of pre-neoplastic conditions, where 
targeted biopsy sampling as opposed to random biopsies is 
likely to achieve optimum cost-effectiveness for patients.
Design of a screen for cell surface markers of 
early gastric cancer
Proteins reported to be overexpressed on the surface 
of advanced gastric cancers include SLC3A2 [11], CDH17 
[12], EPHA2, FGFR2 [13], and CD44v8-10 [14]. To 
focus our search on putative membrane protein markers 
that are elevated in early gastric cancers, we designed a 
screen based on known molecular events in early stages 
of gastric carcinogenesis. Gastric adenocarcinomas are 
strongly associated with Helicobacter pylori infection [15] 
and chronic gastritis [1]. The H. pylori CAG pathogenicity 
island codes for a type IV secretion system, which injects 
the CagA protein from the bacterium into the host 
epithelium [15]. Once in the host cell, CagA dysregulates 
a number of key pathways controlling proliferation, 
differentiation and polarity [16], initiating the process of 
carcinogenesis. We hypothesized that at least a fraction 
of the membrane proteins upregulated by the presence of 
CagA are likely to be retained in gastric cancer through 
the principle of non-oncogene addiction [17]. To focus on 
CagA related changes that are markers of cancer (not of 
infection or hyperplasia), a second ‘virtual’ screen was 
performed in existing mRNA expression databases of 
gastric cancer in comparison to normal tissue.
Here the results of this 2-step screening approach are 
reported, highlighting the identification of CEACAM6 as 
a potential endoscopic biomarker of early gastric cancer. 
We show that the cell surface protein CEACAM6 is 
upregulated by the H. pylori CagA oncoprotein, and highly 
expressed on early gastric cancers as well as premalignant 
lesions. A fluorescently tagged antibody to CEACAM6 
avidly binds to gastric cancer tissue and can be visualized 
by commercially available endoscopic methods.
RESULTS
Two-step screening identifies CEACAM6 to be 
upregulated by CagA, and retained in gastric 
cancer
An ideal screening methodology using cell lines is 
one where the experimental and control groups differ by a 
single acute perturbation, to minimize chronic adaptation 
in culture. MKN28 gastric epithelial cells [18] containing 
a stable CagA expression cassette under a tetracycline 
response element [19] were used in our screen (WT-
A10 cells). These cells retain the capacity to dysregulate 
β-catenin [19], and induce the expression of key intestinal 
transdifferentiation markers (CDX1 and MUC2) on 
CagA expression, confirming the line as a valid model 
for the preliminary phase of the screen. The expression 
of CagA upon induction in this cell line was confirmed 
using RT-PCR, and these cells reproduced the phenotypic 
changes previously described for in vitro CagA expression 
(Supplementary Figure 1).
For the screen, expression of CagA was induced 
by the withdrawal of doxycycline for 48h, followed by 
gene expression array analysis to identify differentially 
regulated genes. Our analysis focused on those transcripts 
that putatively code for intrinsic, extrinsic, integral and 
anchored membrane proteins, based on gene ontology. 
The top ten differentially upregulated membrane protein 
transcripts identified in this cellular assay (Table 1) were 
interrogated in a gene expression cohort of gastric cancers 
and normal controls [20]. Among the hits identified in the 
CagA screen, 4 of them (MMP1, CEACAM6, ITGA2, C3) 
showed at least 2-fold increases in gastric cancer when 
compared to normal controls (Table 1).
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CEACAM6 was chosen for further analysis on the 
basis of its increased levels in gastric cancer over normal 
tissue (8-fold in the SGCC data set). RT-PCR analysis 
on the same MKN28 CagA inducible cell line showed a 
time-dependent increase in CEACAM6 transcripts with 
CagA induction, peaking at 48h post induction in this 
system (Figure 1A). Levels of the CEACAM6 protein 
were also higher after CagA induction, as evidenced by 
flow cytometry analysis using an antibody to CEACAM6 
(Figure 1B). Furthermore, infection of wild-type MKN28 
cells by a live CagA wild-type H. pylori strain also 
resulted in an increase in CEACAM6 transcripts (Figure 
1C), confirming this association to be physiological and 
not an artifact of high levels of overexpression in the tet-
inducible system. The high expression of CEACAM6 
transcripts in gastric cancer was confirmed using other 
publicly available datasets of gastric cancer gene 
expression [21–24] (Figure 2A). Evaluation of CEACAM6 
transcript levels using RNA-seq data of matched tumor 
and adjacent normal tissue, from the SGCC (n=15) and 
TCGA (n=29) also confirmed a significant enrichment of 
the transcript in gastric cancer (Figure 2B). Together, these 
data suggest that CEACAM6 mRNA is upregulated by the 
presence of H. pylori CagA, and is retained in advanced 
gastric cancers.
Quantitative histopathology confirms CEACAM6 
upregulation in gastric cancers compared to 
regions of matched adjacent normal tissue
The Vectra 2 multispectral microscopy platform 
allows a quantitative assessment of antibody staining in 
histological samples [25]. First, this multispectral imaging 
system allows creation of a unique spectral profile for 
every chromogen used with the sample [26], thereby 
enabling the ‘unmixing’ of the chromogen signal from 
a counterstain (Supplementary Figure 2). The unmixed 
chromogen signal can be quantitated in terms of mean 
optical density per unit area of the tumor/normal tissue 
region, to give a numerical readout of protein expression, 
which we demonstrate to correlate well with pathologist 
scoring for a control marker (Supplementary Figure 3).
Accordingly, this platform was used to confirm 
the overexpression of CEACAM6 protein in a 
Table 1: CagA regulated cell surface proteins and their expression in gastric cancer
UniGene Gene Description WT-A10 (CagA +/-) 
Microarray
SGCC
GC Microarray
Fold
Change
p-value Fold
Change
p-value
Hs.201877 TMPRSS11E Transmembrane protease, serine 11E 10.27 1.95E-04 0.97 1.96E-01
Hs.368912 DPP4 Dipeptidyl-peptidase 4 2.97 9.77E-04 1.70 3.12E-05
Hs.83169 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 2.88 4.11E-03 2.18 1.46E-06
Hs.525105 SLITRK6 SLIT and NTRK-like family, member 6 2.70 1.21E-02 1.16 4.02E-02
Hs.86447 TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 2.67 5.64E-04 0.95 2.18E-02
Hs.466814 CEACAM6 Carcinoembryonic antigen-related cell adhesion molecule 6 2.53 5.76E-04 8.06 9.36E-19
Hs.631594 LYPD3 LY6/PLAUR Domain Containing 3 2.49 8.73E-04 1.15 6.08E-03
Hs.247879 C6orf25 Chromosome 6 open reading frame 25 2.30 6.56E-03 0.91 6.35E-08
Hs.369520 SYTL2 Synaptotagmin-like 2 2.30 2.92E-02 0.70 1.44E-06
Hs.482077 ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 2.23 1.03E-04 2.32 8.53E-24
Hs.647419 CD68 CD68 molecule 2.19 1.97E-03 1.16 7.48E-05
Hs.529053 C3 Complement Component 3 2.19 1.19E-02 2.08 1.01E-10
A list of putative cell surface proteins transcriptionally upregulated by overexpression of CagA-microarray analysis 
performed on the Gene 1.0 ST platform using an inducible cagA cell line. Top hits were screened through microarray 
databases of Gastric Cancer vs. normal tissue from the Singapore Gastric Cancer Consortium (SGCC) GSE15460 
(Normal=85, Tumor=189).
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Figure 1: CEACAM6 expression is upregulated by CagA and H. pylori infection. A. RT-PCR showing the time course of 
CEACAM6 transcript upregulation after CagA induction, in relation to CagA levels in the CagA inducible WT-A10 cell line. CT values are 
normalized to 18S RNA and shown relative to CEACAM6 or CagA levels before CagA induction to demonstrate fold change. Mean±SD, 
n=3. B. Flow cytometric histogram of CEACAM6 protein levels in CagA-negative (baseline) and CagA-positive (induced) cells, showing 
elevated CEACAM6 protein levels 48h after CagA induction. C. RT-PCR showing that H. pylori infection upregulates CEACAM6. MKN28 
cells were infected with increasing MOI’s of isogenic wild-type H. pylori and CEACAM6 transcripts were measured by RT-PCR 24h after 
infection. Mean±SD, n=3. Unpaired t test, ns = not significant.
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tissue microarray of advanced gastric cancer with 
matched normal tissue (n=29). Consistent with earlier 
reports [27], a significant increase in CEACAM6 
immunostaining for gastric cancer in comparison 
to adjacent normal tissue was noted (Figure 3A and 
3B), p < 0.001. A larger in-house tissue microarray 
generated at National University Hospital, Singapore, 
also showed a significant enrichment of CEACAM6 
expression in tumor cores (Figure 3C), p < 0.001. A 
receiver-operative characteristic (ROC) analysis of 
the larger tissue microarray yielded an area under the 
curve (AUC) of 0.880 for the discrimination of cancer 
from normal samples by CEACAM6 (Figure 3D). This 
group of samples was further divided into CEACAM6 
“high/low” groups across the median value, based on 
the staining intensity readouts depicted in Figure 3C, 
to perform overall survival analysis. The CEACAM6 
“high” group of patients showed a trend towards poorer 
overall survival (Figure 3E). Median staining intensity 
numerically increased with tumor stage, however it is 
not significantly different between respective tumor 
stage groups. Furthermore, CEACAM6 high staining 
cases were not associated with any specific tumor 
morphology or tumor grade (Supplementary Figure 4).
CEACAM6 levels are elevated in early gastric 
cancer and dysplastic lesions
As CEACAM6 levels increase in response to H. 
pylori CagA (an early event in carcinogenesis) and are 
Figure 2: Gene expression analysis of gastric cancers show an enrichment for CEACAM6. A. Dot plot of relative CEACAM6 
transcript levels in gene expression arrays of gastric cancer in comparison to normal stomach tissue (GSE15460 (SGCC) – Normal=85, 
Tumor=185; GSE13861 - Normal=19, Tumor=65). Median, unpaired t test. B. Plot of relative CEACAM6 transcript levels using RNA-seq 
analysis of matched gastric cancers compared to normal adjacent tissue (SGCC n=15, TCGA n=29). Paired t test.
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retained in advanced cancers, we hypothesized that it may 
be a marker of early gastric cancer. To test this hypothesis 
we obtained a commercial tissue microarray of early gastric 
cancers (clinical stage I, n=70) with matched adjacent 
normal tissue. This microarray was stained for CEACAM6, 
and quantitated on the Vectra 2 platform as described 
earlier. We observed a clear increase in the mean staining 
intensity for CEACAM6 in early gastric cancers (T1N0M0 
and T1N1M0) when compared to adjacent normal tissue 
(Figure 4A), p < 0.001. CEACAM6 staining provided an 
AUC of 0.831 in an ROC analysis for the distinction of 
normal mucosa from early gastric cancer (Figure 4B).
In a cohort of dysplastic gastric lesions, a 
significant increase in CEACAM6 expression levels was 
noted, in comparison to matched normal tissue within 
the section (Figure 4C). Of 20 cases of dysplasia (10 
high grade and 10 low grade), 7 and 8 cases respectively 
showed a complete spectrum of states from normal 
to intestinal metaplasia (IM) to dysplastic mucosa. 
An overexpression of CEACAM6 in the dysplastic 
Figure 3: CEACAM6 protein expression by quantitative immunohistochemistry in gastric cancers. A. Representative 
images acquired from a tissue microarray of gastric cancers and matched normal tissues stained for CEACAM6 using standard 
immunohistochemical methods. Scale bar=50μm. B. Images obtained as depicted in A were quantified using the Vectra 2 system. 
Commercially available gastric adenocarcinoma tissue microarray consisting of 29 cases of matched normal distant tissue (NDT), normal 
adjacent tissue (NAT) and tumor (T), shows stronger CEACAM6 staining within regions of cancer compared to adjacent normal tissue. 
Paired t test. C. Upregulation of CEACAM6 protein in gastric cancer was also confirmed using a local gastric adenocarcinoma tissue 
microarray (National University Hospital, Singapore). Normal=82, Tumor=158. Median, unpaired t test. D. ROC analysis was performed 
on tissue array set shown in C, which yielded an AUC of 0.88 for the diagnosis of gastric cancer using CEACAM6 IHC. E. Overall survival 
analysis of 106 gastric cancer patients. Cases were divided into CEACAM6 high/low groups across the median value, based on scoring 
readout shown in C. CEACAM6 high group shows a significant trend towards poorer overall survival. Log-rank (Mantel-Cox) test.
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area was observed, with a significant increase in the 
H-Score for CEACAM6 staining compared to adjacent 
normal gastric mucosa, p = 0.003 (Figure 4D). The 
quantification of CEACAM6 scores for dysplastic 
lesions was done by an experienced histopathologist, 
to avoid errors from the automated Vectra 2 algorithm 
due to subtle features of these lesions. Interestingly, the 
expression of CEACAM6 was highest in the IM area as 
compared to the adjacent normal and dysplastic mucosa. 
In contrast, minimal staining of CEACAM6 occurred in 
regions of chronic gastritis, the most prevalent lesion 
associated with H. pylori infection [28] (Figure 4C).
Together, these findings suggest that CEACAM6 may 
be useful as a surface marker of early gastric cancer and pre-
neoplastic lesions. The marked increase in immunoreactivity 
to CEACAM6 in dysplastic and early neoplastic lesions over 
adjacent normal tissue is promising for the development of 
a biomarker for endoscopy, where a significant challenge is 
identifying the correct region to biopsy.
Figure 4: CEACAM6 is upregulated in both early gastric cancers and dysplastic lesions of the stomach. A. CEACAM6 
IHC staining of an early gastric adenocarcinoma tissue microarray with matched normal adjacent tissue (clinical stage 1 - T1N0M0 and 
T1N1M0=32, T2N0M0=39). Paired t test. B. ROC analysis of CEACAM6 staining in T1 early gastric cancer shows an AUC of 0.831 
for the identification of early gastric cancer from adjacent normal tissue. C. A representative image of CEACAM6 staining in a region of 
dysplasia depicting increase in staining intensity from normal gastric glands showing mild chronic gastritis (N+CG) to intestinal metaplasia 
(IM) to dysplasia (D). Scale bar=100μm. D. Quantitation of the H-Score for CEACAM6 in 20 cases of dysplasia with adjacent normal 
tissue performed by a histopathologist. A significant increase in CEACAM6 staining is observed in dysplastic regions. Paired t test.
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A fluorescently labeled antibody to CEACAM6 
binds avidly to gastric cancer tissue ex vivo
A surface protein such as CEACAM6 could serve 
as a marker to identify gastric malignant pathology, 
target biopsies to the right site, and provide a means of 
lesion resection in real time. As a proof of concept for 
the potential utility of CEACAM6, we aimed to evaluate 
the ability of a conjugated anti-CEACAM6 reagent to 
directly bind gastric cancer tissue. A monoclonal antibody 
to CEACAM6 was conjugated covalently to Alexa Fluor 
488 and purified through size exclusion chromatography 
(Supplementary Figure 5A). The ability of this reagent to 
bind to five freshly resected patient derived xenografts 
(PDX) of gastric cancer in a direct staining assay was 
tested (experiment schematic in Figure 5A). To simulate 
the setting of utilizing this marker during endoscopy, 
fluorescent images of the stained PDX samples were 
Figure 5: Ex vivo staining of a fluorescently conjugated antibody to CEACAM6 and visualization with a confocal laser 
endomicroscopy probe. A. Schematic diagram of the experimental plan. Freshly resected patient derived xenografts (PDXs) of gastric 
cancer were divided into two pieces - one section was used for direct fluorescent staining and the remainder for immunohistochemistry. B. 
Representative images from freshly resected gastric cancer xenograft tumors without fixation showing clearly visible fluorescence signal 
from the CEACAM6 antibody conjugated to Alexa Fluor 488 (imaged with a Cellvizio confocal laser endomicroscopy probe, compatible 
with commercial endoscopy equipment). CEACAM6 IHC staining of the same xenograft is shown for reference. Scale bar=50μm. C. 
Analysis of signal intensity of CEACAM6-AF 488 stained tumors in comparison to unstained controls, as shown in B, n=5. Paired t test. 
D. Correlative analysis of Cellvizio CEACAM6-AF 488 fluorescence intensity values with CEACAM6 IHC staining intensity, as shown 
in B, n=5.
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obtained using a clinically approved Cellvizio confocal 
endomicroscopy probe (Mauna Kea Technologies), which 
is compatible with commercial endoscopy systems. We 
demonstrate low background signal from unstained tumor 
tissue with strong and clear fluorescent signal from tissue 
samples that have been exposed to anti-CEACAM6 
Alexa Fluor 488 conjugated antibody for 30 minutes at 
room temperature (Figures 5B and 5C, Supplementary 
Figure 5B). A video recording of the CEACAM6 signal 
obtained from the resected gastric PDX tissue using the 
confocal probe offers a representation of the endoscopic 
visualization of tumor tissue (Supplementary movie 1). 
Since PDX models do not have an appropriate negative 
control of normal tissue with human CEACAM6, we 
correlated the fluorescent signal of the Alexa Fluor 488 
anti-CEACAM6 conjugate with the amount of CEACAM6 
estimated for each tumor by quantitative histopathology. 
Each tumor was divided into 2 sections, one of which was 
stained directly with the fluorescent antibody, and the 
other was fixed for staining with routine IHC analysis. 
A correlation between the two data sets was observed, 
moreover a tumor negatively staining for CEACAM6 by 
IHC also showed minimal staining with the fluorescently 
conjugated reagent (Figure 5D, Supplementary Figure 
5B). Together, these results suggest that a fluorescently 
labelled CEACAM6 antibody can directly bind to live 
gastric cancer tissue and therefore have applicability in 
the context of endoscopic diagnosis of early gastric cancer.
DISCUSSION
In this paper, we aimed to identify a candidate cell-
surface biomarker for use in fluorescence endoscopy for 
the diagnosis of early gastric cancer. We chose to use a 
CagA based screen, since CagA exogenous expression 
in the epithelium is sufficient for development of gastric 
cancer in mice, even in the absence of H. pylori infection 
[29], confirming its activity as a genuine oncoprotein. 
Indeed, despite the prevalence of H. pylori infection in 
the general population, a significant increase in CAG 
pathogenicity islands in cancer is noted when compared to 
dysplastic or normal tissue [30]. Generation of a cell line 
that inducibly expresses the CagA protein [19] allowed 
a controlled, cell-based assay to identify CEACAM6 as 
a novel cell-surface target upregulated by the oncogene.
CEACAM6 has previously been reported to be 
upregulated in a variety of cancers, including gastric 
cancer [27] but its biological role remains unclear. 
It is a cell-adhesion protein, capable of a variety of 
homotypic and heterotypic interactions, mediating cell-
cell interactions. The binding partners of CEACAM6 
are not well characterized, but it has been described 
to promote in vivo metastasis, tumor angiogenesis, 
vasculogenic mimicry in gastric cancer, and confers a 
poor prognosis to cancers overexpressing the protein 
[31]. Here, we demonstrate that it is highly expressed in 
pre-malignant lesions of the stomach and early gastric 
cancer, with significant clinical implications for early 
diagnosis and targeting of biopsies. The lower expression 
of CEACAM6 in regions of chronic gastritis is also 
significant, as a putative marker would ideally need to 
distinguish pre-neoplastic lesions from gastritis, which is 
far more prevalent in patients with H. pylori [28]. The ‘hit 
and run’ model [32] for H. pylori carcinogenesis, whereby 
H. pylori infection may be a transient initiating event, 
suggests that while CagA is critical to the onset of gastric 
carcinogensis, it is not always required for maintenance 
of the oncogenic phenotype. The pro-oncogenic actions 
of CagA are supplanted by a series of other pathway 
alterations that continue the process of carcinogenesis 
[32], and our data suggest that CEACAM6 may be one 
of these altered pathways that is retained through non-
oncogene addiction [17].
The few reports that exist on marker-guided 
gastroscopy focus on the use of fluorescently conjugated 
antibodies to carcinoembryonic antigen (CEA) or 
MUC1 [33], with limited clinical validation. A marker 
that highlights early lesions could decrease the chances 
of false negative biopsies, and enabling reliable follow 
up. We show that a fluorescently conjugated antibody 
to CEACAM6 is able to bind to gastric cancer samples 
from xenografts, and be visualized by a confocal laser 
endomicroscopy (CLE) probe that is compatible with most 
commercially available endoscopy equipment. While CLE 
imaging on its own has been shown promise in identifying 
superficial gastric neoplasia [35], it requires significant 
time to cover the entire surface area of the stomach for a 
thorough evaluation. In our study, we demonstrate that a 
fluorescent marker to the cell surface protein CEACAM6 
could complement this technique, by providing a ‘beacon’ 
to high risk regions that may be assessed further either 
by confocal imaging or histological analysis after biopsy. 
The compatibility of the Cellvizio system with existing 
equipment will facilitate clinical research to confirm 
its utility in this setting. There are several fluorophores 
approved by the FDA for human use [34] but concerns 
remain about their efficacy in the acidic pH of the native 
stomach, and the ability of an antibody conjugate to 
penetrate through the mucin layer. However, cancers often 
disrupt the mucin layer, and the pH can be altered through 
pre-treatment with proton pump inhibition, allowing for 
the design of trials to evaluate such reagents in early 
gastric cancer diagnosis. The high levels of discrimination 
demonstrated by the AUC of CEACAM6 in early gastric 
cancer and intestinal metaplasia specimen suggest a 
rationale for the further development of this reagent as a 
tool for early gastric cancer diagnosis, in conjunction with 
advances in fluorescent endoscopy.
In summary, this work uses a CagA based in 
vitro screen which identified CEACAM6 as a novel 
biomarker of early gastric cancer and dysplastic lesions, 
and demonstrated the ability of a commercial endoscopy 
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system to detect fluorescently labelled CEACAM6 reagent 
in ex vivo preparations of gastric cancer. The results show 
a potential clinical utility of a fluorescently conjugated 
CEACAM6 antibody for the endoscopic diagnosis of early 
gastric cancer.
MATERIALS AND METHODS
Cell culture, H.pylori infection, qPCR and flow 
cytometry
WT-A10 cell line is a MKN28-derived stable 
transfectant clone that inducibly expresses CagA using 
a tet-off system [19]. WT-A10 cells were cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS), 10 mM HEPES, 1 mM sodium pyruvate, 
0.1 mM non-essential amino acid, penicillin G sodium 
& streptomycin sulfate, 2 mM L-glutamine, 0.5 mg/ml 
G418, 0.1 mg/ml hygromycin B and 1 μg/ml Doxycycline. 
MKN28 human gastric epithelial cells were cultured in 
RPMI 1640 medium supplemented with 10% FBS.
The H. pylori isogenic wild-type strain 
(NCTC11637) was cultured in Trypticase soy agar with 
5% sheep blood (BD Biosciences) at 37°C in humidified 
and microaerophilic atmosphere to form colonies. The 
colonies were inoculated in Brucella broth (Sigma-
Aldrich) with 10% FBS for 24h to prepare broth cultures. 
Gastric cancer cell lines were infected with broth-cultured 
H. pylori at 0, 20, 50 and 100 MOI for 24h.
Total RNA was extracted using the RNeasy 
Mini Kit (Qiagen), and cDNA was synthesized with 
the iScript RT kit (Bio-Rad Laboratories) according 
to the instructions from the manufacturer. qPCR was 
performed with the KAPA SYBR FAST qPCR Kits (Kapa 
Biosystems, Wilmington, MA) using CEACAM6 specific 
oligonucleotide primers (GACCCTCACTCTACTCAGC 
and CAGATTTTCCCCTGGACG) for SYBR Green-
based measurements. Data analyses were performed 
on ABI Prism 7500 real-time PCR system (Applied 
Biosystems) and gene expression data were normalized to 
18S or GAPDH levels.
CagA induced and non-induced WT-A10 cells were 
incubated with anti-CEACAM6 antibody (9A6, Abcam) 
or AF488 tagged anti-mouse IgG and counterstained 
with 1 ug/ml of propidium iodide after fixation. Cells 
were analyzed on a BD LSRII flow cytometer (BD 
Biosciences). Flow cytometry data were analyzed using 
the FlowJo computer software package (Tree Star, USA).
Microarray analysis
RNA from WT-A10 cells was hybridized on 
Affymetrix GeneChip Human Gene 1.0 ST array. 
Following hybridization, array was washed and stained 
according to the standard Affymetrix protocol using 
Fluidics Station 450, GeneChip Scanner 3000 7G was 
used to measure the fluorescence intensity emitted by 
the labelled target. The raw data was subjected to further 
processing using the Affymetrix GeneChip Operating 
Software. Top hits obtained from CagA microarray 
analysis were screened through gastric cancer dataset 
from the Singapore Gastric Cancer Consortium (SGCC), 
GSE15460, and GSE13861 (PMID: 21447720). RNA-seq 
datasets were obtained from SGCC (matched, n=15) and 
TCGA (matched, n=29).
Immunohistochemistry and quantitative analysis
Tissue microarray of gastric cancers (Normal=82, 
Tumor=158, matched n=46), as well as low and high 
grade dysplasia (n=20) were obtained from National 
University Hospital, Singapore. Tissue microarrays 
obtained from US Biomax Inc., Rockville, USA consisted 
of gastric adenocarcinoma (HStm-Ade090PG-01; normal 
distant tissue, normal adjacent tissue and tumor, n=29, 
3 cores/case) and early gastric adenocarcinoma (HStm-
Ade150CS1-01; T1N0M0=29, T1N1M0=3, T2N0M0=39 
and matched normal adjacent tissue, 2 cores/case).
Slides were deparaffinized in xylene three times 
for 5 minutes and rehydrated in an ethanol gradient 
100%, 90%, 70% and H2O for 5 minutes each. Pressure 
antigen retrieval was performed in citrate antigen 
retrieval buffer pH 6.0 (Dako) using a Retriever device 
(Electron Microscopy Sciences). Slides were stained 
using a standard automated immunohistochemistry 
protocol (Bond-Max, Leica Biosystems). Briefly, slides 
were blocked for 30 minutes with antibody diluent 
(Bond Primary Antibody Diluent, Leica Biosystems) and 
subsequently incubated with CEACAM6 antibody for 30 
minutes. Detection was performed using a polymer HRP 
detection system (Bond Polymer Refine Detection, Leica 
Biosystems) and 3,3′-diaminobenzidine (DAB) was used 
for visualization. Slides were incubated with hematoxylin 
to serve as a counterstain.
Acquisition and image analysis was done with 
the Vectra 2 multispectral automated imaging system 
(PerkinElmer) and inForm 2.0 image analysis software, 
an interactive image segmentation system, as described 
in previous studies [26]. Nuance software (PerkinElmer) 
was employed to build the spectral libraries for the 
chromogens (DAB and hematoxylin). These chromogen 
signature profiles were later used to spectrally unmix and 
quantitate CEACAM6 staining intensity, with appropriate 
regions for analysis chosen by a pathologist.
Antibody conjugation and confocal laser 
endomicroscopy
Briefly, 25μg of antibody was purified from carrier 
and mixed with bicarbonate buffer. The purified antibody 
was conjugated to Alexa Fluor 488 (final concentration 
120μM) at room temperature and incubated in the 
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dark. The conjugated antibody was purified using Bio-
Gel P-30 size exclusion chromatography (Bio-Rad, 
chromatography, 90-180μm wet bead size).
Gastric cancer patient derived xenografts (PDX, 
n=5) were obtained from the Xenograft Cancer Models 
Facility (Cancer Science Institute of Singapore, NUS) 
and transferred to sterile phosphate buffered saline (PBS) 
immediately after resection. Each sample was divided 
into two: one part was used for formalin-fixation and 
IHC analysis of CEACAM6 levels as described above, 
and the second part was stained using Alexa Fluor 488 
conjugated CEACAM6 antibody (1:100 dilution) for 
30 minutes. Normal murine stomach tissue served as a 
negative control. After routine washes, dynamic images 
were recorded using a hand-held confocal endomicroscopy 
(Mauna Kea Technologies) probe directly applied both to 
the internal part and several areas of surrounding tissue.
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